Literature DB >> 8020798

Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.

J C Delchier1, F Roudot-Thoraval, L Stanescu, M C Deharvengt, L Elouaer Blanc.   

Abstract

The gastrojet, a closed loop pH feedback infusion pump capable of maintaining intragastric pH at a target value by infusing H2 blockers at variable rates, was used to assess factors influencing the quantity of famotidine required to maintain intragastric pH above 4 for 24 hours in 34 fed patients with duodenal ulcers. The following factors were considered: sex, age, duration of the disease, previous bleeding, previous poor response to H2 blockers (ulcer unhealed at six weeks, or recurrence within three months during maintenance treatment), activity of the ulcer disease, smoking habits, cirrhosis. The patients had taken no antisecretory drugs for the 15 days before the study. Two standardised meals were given during the study period (from 1000 to 1000). Fifty ml of famotidine (4 mg/ml) was loaded into infusion bags and the pump was programmed to deliver the drug intravenously at 11 rates varying from 0 to 40 microliters/min. The target pH was 4. Mean famotidine use was 111 mg (range 33 to 200), the 23 hour median pH was 5.3, and the mean time during which pH was above 4 was 75.4%. There was a negative correlation (p < 0.001) between famotidine delivery and the inhibition of gastric acidity. Statistical analysis showed that only cirrhosis significantly influenced drug delivery, median pH, and the time during which pH was above 4. Mean drug delivery in the cirrhotic and non-cirrhotic patients was 135 v 97 mg (p < 0.04), 23 hour median pH was 4.7 v 5.6 (p < 0.01), and the mean time at pH > 4 was 65.9 v 81.6% (p < 0.01). There were large interindividual variations in famotidine requirements, but not only cirrhosis was predictive of dose requirement. These results suggest that the appropriate amount of famotidine to treat duodenal ulcer in cirrhotic patients is probably higher than the usually recommended dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020798      PMCID: PMC1374871          DOI: 10.1136/gut.35.6.750

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Smoking impairs therapeutic gastric inhibition.

Authors:  E J Boyd; J A Wilson; K G Wormsley
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

2.  Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.

Authors:  T Gledhill; M Buck; R H Hunt
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

3.  Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.

Authors:  S Sontag; D Y Graham; A Belsito; J Weiss; A Farley; R Grunt; N Cohen; D Kinnear; W Davis; A Archambault
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

4.  Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.

Authors:  C J Young; T K Daneshmend; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

5.  Cimetidine or vagotomy? Comparison of the effects of proximal gastric vagotomy, cimetidine and placebo on nocturnal intragastric acidity and acid secretion in patients with cimetidine resistant duodenal ulcer.

Authors:  T Gledhill; M Buck; A Paul; R H Hunt
Journal:  Br J Surg       Date:  1983-12       Impact factor: 6.939

6.  Motor activity of the distal oesophagus and gastrooesophageal reflux.

Authors:  E Corazziari; I Bontempo; F Anzini; A Torsoli
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

7.  Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs.

Authors:  F Di Mario; L Gottardello; B Germanà; P Dotto; S A Grassi; F Vianello; G Battaglia; G Leandro; P Burra; M Salvagnini
Journal:  Ital J Gastroenterol       Date:  1992 Mar-Apr

8.  Influence of cigarette smoking on healing and relapse in duodenal ulcer disease.

Authors:  M G Korman; J Hansky; E R Eaves; G T Schmidt
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

9.  Very long-term treatment of peptic ulcer with cimetidine.

Authors:  J M Cargill; J H Saunders; N Peden; K G Wormsley
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

10.  [Does nocturnal monitoring of gastric pH permit the prediction of therapeutic response in severe duodenal ulcer treated with ranitidine?].

Authors:  J P Galmiche; J L Tranvouez; P Denis; C N'Djitoyap; J F Guillard; P A Lehur; R Colin
Journal:  Gastroenterol Clin Biol       Date:  1985 Aug-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.